The drug manufacturer, Amgen, recently added a warning label to its popular treatment for people who have experienced a loss of energy due to anemia resulting from Chronic Kidney Disease and Chemotherapy after studies with similar medications indicated an increased risk of blood clots ands stroke. Aranesp is a 165-amino acid protein with erythropoiesis stimulating properties (it stimulates the production of hemoglobin and other blood products in patients).

The warning states "erythropoietic therapies may increase the risk of thrombotic and other serious events." This label was added after studies with Eprex and NeoRecormon - similar both chemically and physiologically to Aransep, showed a marked increase in major complications including blood clots, stroke and death when doctors tried to raise patient hemoglobin levels beyond recommended levels.

It was believed by some researchers that the increase in hemoglobin might enhance the effectiveness of chemotherapy and radiation as cancer treatments. Amgen states that the FDA asked the company to add the trial information and warning to the product.

Register your Aranesp Complaint

If you or a loved one has suffered from blood clots or stroke, you may qualify for damages or remedies that may be awarded in a possible class action lawsuit. Please fill in our form on the right to submit your complaint and we will have a lawyer review your Aranesp complaint.

At, it is our goal to keep you informed about important legal cases and settlements. We are dedicated to helping you resolve your legal complaints.

Add Your Comment on This Issue

Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:
Request Legal Help